OncoTarget, ‎1949-2553

Journal

Publications

  1. 2016
  2. Published

    Glutamate Receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer

    Joseph Wragg, Stephen Ward, Victoria Heath, & Roy Bicknell, 12 May 2016, In: OncoTarget. 7, 15, p. 20440-20454

    Research output: Contribution to journalArticlepeer-review

  3. Published
  4. Published
  5. Published

    MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer

    Lindsey Compton, & Zewei Luo, 19 Jan 2016, In: OncoTarget. 7, 3, p. 2417-32 16 p.

    Research output: Contribution to journalArticlepeer-review

  6. 2015
  7. Published

    Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?

    Geoff Brown & , 19 Oct 2015, In: OncoTarget. 6, 41, p. 43326-43341 16 p.

    Research output: Contribution to journalArticlepeer-review

  8. Published

    Development and characterisation of a 3D multi-cellular in vitro model of normal human breast: a tool for cancer initiation studies

    Vera Novitskaya, Fedor Berditchevski, & , 30 May 2015, In: OncoTarget. 6, 15, p. 13731-13741 11 p.

    Research output: Contribution to journalArticlepeer-review

  9. Published

    Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer

    Anthony Kong, 20 Mar 2015, In: OncoTarget. 6, 8, p. 5678-5694 17 p.

    Research output: Contribution to journalArticlepeer-review

  10. 2014
  11. Published

    Human PIF1 helicase supports DNA replication and cell growth under oncogenic-stress

    Eva Petermann, & , 5 Nov 2014, In: OncoTarget. 5, 22, p. 11381-11398 18 p.

    Research output: Contribution to journalArticlepeer-review

  12. Published

    ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer

    Anthony Kong, Aug 2014, In: OncoTarget. 5, 16, p. 6633-6646 14 p.

    Research output: Contribution to journalArticlepeer-review

  13. Published

    Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

    Anthony Kong, 17 Apr 2014, In: OncoTarget. 5, 15, p. 5934-5949 16 p.

    Research output: Contribution to journalArticlepeer-review